Radyoterapi Uygulanan Serviks Kanserli Hastalarda Tedavi Sonuçlarının Değerlendirilmesi ve Prognostik Faktörlerin İncelenmesi

Yıl 2019, Cilt: 2 Sayı: 2, 9 - 22, 30.05.2019

Cenk Ahmet Şen , Melek Gamze Aksu Aylin Fidan Korcum

Öz

Amaç: Radyoterapi (RT) serviks kanserinde kullanılan etkili bir tedavi yöntemidir. Bu çalışmanın amacı RT uygulanmış serviks kanserli hastaların tedavi sonuçları ve prognostik faktörler açısından değerlendirilmesidir.

Gereç ve yöntem: Kliniğimizde adjuvan ve definitif RT uygulanmış evre IB-IVA serviks karsinomlu toplam 142 hasta retrospektif olarak incelendi. Ortalama izlem süresi 30 ay olup, tedaviye bağlı yan etkiler, sağkalım oranları ve prognostik faktörler değerlendirildi.

Bulgular: Bu çalışmada, RT alan tüm hastalarda evre, tedavi öncesi hemoglobin değeri, toplam RT süresi, eş zamanlı kemoterapi (KT) uygulanması, lenfovasküler invazyon durumu, tümör çapı ve RT sonrası rezidü tümör varlığı sağkalımda etkili prognostik faktörler olarak saptandı. Adjuvan ve definitif RT uygulanan hastalar arasında RT yan etkileri açısından anlamlı fark görülmedi.

Sonuç: RT serviks kanseri tedavisinde kabul edilebilir komplikasyon oranları ile tolere edilebilir ve etkili bir tedavi yöntemidir. Yan etkilerin değerlendirilmesinde geniş hasta sayılarını içeren prospektif çalışmalara gereksinim vardır.

Anahtar Kelimeler

Serviks kanseri, Radyoterapi, Prognostik faktörler

Kaynakça

• 1. Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France, GLOBOCAN 2018, World Health Organization. http://globocan.iarc.fr
• 2. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology, Version
• 2. Cervical Cancer, https://www.nccn.org
• 3. Viani GA, Manta GB, Eduardo JS, et al. Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy - a meta-analysis of clinical trials. J Exp Clin Cancer Res 2009;28:47.
• 4. Endo D, Todo Y, Okamoto K, et al. Prognostic factors for patients with cervical cancer treated with concurrent chemoradiotherapy: a retrospective analysis in a Japanese cohort. J Gynecol Oncol 2015;26(1):12-18.
• 5. Wang SC, Lin LC, Yu-Ting K, et al. Radiographic number of positive pelvic lymph nodes as a prognostic factor in cervical cancer treated with definitive concurrent chemoradiotherapy or intensity-modulated radiotherapy. Front Oncol 2018;8:546.
• 6. Chen CC, Wang L, Lin JC, et al. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy. J Formos Med Assoc 2015;114(3):231-237.
• 7. National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology, Cervical Cancer, Version 3. https://www.nccn.org/ professionals/physician_gls/
• 8. Marth C, Landoni F, Mahner S, et al. ESMO Guidelines Committee. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Supplement 4).
• 9. Perez CA, Grigsby PW, Chao KS, et al. Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiation Oncology Biol Phys 1998;41(2):307-317.
• 10. Takeshi K, Katsuyuki K, Yoshiaki T, et al. Definitive radiotherapy combined with high dose rate brachytherapy for stage III carcinoma of the uterine cervix: Retrospective analysis of prognostic factors concerning patient characteristicks and treatment parameters. Int J Radiation Oncology Biol Phys 1998;41(2):319-327
• 11. Perez CA, Breaux S, Madoc-Jones H, et al. Radiation therapy alone in the treatment of carcinoma of uterine cervix. I. Analysis of tumor recurrence. Cancer 1983;51:1393-1402
• 12. Montana GS, Fowler WC, Varia MA, et al. Carcinoma of the cervix, stage III. Results of radiation therapy. Cancer 1986;57:148-154
• 13. Kim RY, Trotti A, Andy T, et al. Radiation alone in treatment of cancer of the uterine cervix: analysis of pelvic failure and dose response relationship. Int J Radiation Oncology Biol Phys 1989;17(5):973- 978.
• 14. Eifel PJ, Morris M, Oswald MJ, et al. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. Cancer 1990;65:2507-2514.
• 15. Eifel PJ, Burke TW, Morris M, et al. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995;59(1):38-44.
• 16. Katanyoo K, Sanguanrungsirikul S, Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol 2012;125(2):292.
• 17. Galic V, Herzog TJ, Lewin SN, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 2012;125(2):287.
• 18. Lee YY, Choi CH, Kim TJ, et al. A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IBIIA. Gynecol Oncol 2011;120(3):439.
• 19. Berek JS, Castaldo TW, Hacker NF, et al. Adenocarcinoma of the uterine cervix. Cancer 1981;48:2734-2741.
• 20. Williams NL, Werner TL, Jarboe EA, et al. Adenocarcinoma of the cervix: should we treat it diffrently? Curr Oncol Rep 2015;17(4):17.
• 21. Grinsky T, Pejovic-Lenfant MH, Bourhis J, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of cervix treated by radiation therapy: Results of a retrospective study of 386 patients. Int J Radiation Oncology Biol Phys 1989;16(1):37-42.
• 22. Yalman D, Aras AB, Ozkok S, et al. Prognostic factors in definitive radiotherapy of uterine cervical cancer. Eur J Gynaecol Oncol 2003;24(3-4):309-314.
• 23. Hoskin PJ, Rojas AM, Peiris SN, et al. Pretreatment haemoglobin and peripheral blood lymphocyte count as independent predictors of outcome in carcinoma of cervix. Clin Oncol (R Coll Radiol) 2014;26(4):179-184.
• 24. Shin NR, Lee YY, Kim SH, et al. Prognostic value of pretreatment hemoglobin level in patients with early cervical cancer. Obstet Gynecol Sci 2014;57(1):28-36.
• 25. Lanciano RM, Pajak TF, Martz K, et al. The inflence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns of care study. Int J Radiation Oncology Biol Phys 1993;25(3):391-397.
• 26. Perez CA, Grigsby PW, Castro-Vita H, et al. Carcinoma of the uterine cervix. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. Int J Radiation Oncology Biol Phys 1995;32(5):1275-1288.
• 27. Fyles A, Keane TJ, Barton M, et al. The effct of treatment duration in the local control of cervix cancer. Radiother Oncol 1993;28(2):179-180.
• 28. Delaloye JF, Coucke PA, Pampallona S, et al. Effct of total treatment of time on event free survival in carcinoma of the cervix. Gynecol Oncol 1996;60(1):42-48.
• 29. Lin SM, Ku HY, Chang TC, et al. The prognostic impact of overall treatment time on disease outcome in uterine cervical cancer patients treated primarily with concomitant chemoradiotherapy: a nationwide Taiwanese cohort study. Oncotarget 2017;8(49):85203-85213.
• 30. Pathy S, Kumar L, Pandey RM, et al. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma. Asian Pac J Cancer Prev. 2015;16(12):5075-5079.
• 31. Ramey SJ, Asher D, Kwon D, et al. Delays in definitive cervical cancer treatment: An analysis of disparities and overall survival impact. Gynecol Oncol. 2018;149(1):53-62.
• 32. Kim TH, Kim MH, Kim BJ, et al. Prognostic Importance of the Site of Recurrence in Patients With Metastatic Recurrent Cervical Cancer. Int J Radiat Oncol Biol Phys. 2017; 98(5):1124-1131.
• 33. Huang YT, Wang CC, Tsai CS, et al. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. Int J Radiat Oncol Biol Phys 2012;84(2):420-7.
• 34. Lanciano RM, Martz K, Coia LR, et al. Tumor and treatment factors improving outcome in stage IIIB cervix cancer. Int J Radiation Oncology Biol Phys 1991;20(1):95-100.
• 35. Lee SW, Suh CO, Chung EJ et al. Dose optimization of fractionated external radiation and high dose rate intracavitary brachytherapy for FIGO stage IB uterine cervical carcinoma. Int J Radiat Oncol Biol Phys 2002;52:1338-1344.
• 36. Storey MR, Pollack A, Zagars G, et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Physc 2000;48(3):635-642.